Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

This study evaluates whether surgery to remove recurrent ovarian cancer (when it comes back a second time) followed by the PARP inhibitor niraparib improves outcomes compared to drug treatment alone, in patients with platinum-sensitive ovarian cancer. **You may be eligible if...** - You are between 18 and 75 years old - You have ovarian, peritoneal, or fallopian tube cancer that has come back a second time and is still sensitive to platinum-based chemotherapy - A surgeon has assessed that complete removal of all visible cancer is possible - Depending on your cohort: you may or may not have previously used a PARP inhibitor or had prior cytoreductive surgery **You may NOT be eligible if...** - Complete surgical removal is not feasible - Your cancer is not platinum-sensitive - Your performance status or organ function does not meet requirements Talk to your doctor to see if this trial is right for you.